Crinecerfont Lowers Elevated Hormone Markers in Adults with 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia.

Richard J Auchus Kyriakie SarafoglouPatricia Y FechnerMaria G VogiatziErik A ImelShanlee M DavisNagdeep GiriJulia SturgeonEiry RobertsJean L ChanRobert H Farber

Published in: The Journal of clinical endocrinology and metabolism (2021)

Crinecerfont treatment for 14 days lowered ACTH and afforded clinically meaningful reductions of elevated 17OHP, androstenedione, testosterone (women), or androstenedione/testosterone ratio (men) in adults with 21OHD. Longer-term studies are required to evaluate the effects of crinecerfont on clinical endpoints of disordered steroidogenesis and glucocorticoid exposure in patients with 21OHD.

Keyphrases

replacement therapy
polycystic ovary syndrome
smoking cessation
type diabetes
combination therapy
gestational age
adipose tissue
insulin resistance
breast cancer risk